The constant region of an antibody, also known as the Fc region, is crucial for its effector functions. It determines the class or isotype of the antibody (such as IgG, IgM, IgA, IgE, or IgD), influencing its distribution and function in the body. For instance, IgG can cross the placenta, providing passive immunity to the fetus, while IgE is involved in allergic responses. The Fc region also interacts with Fc receptors on the surface of various immune cells, such as macrophages and neutrophils. This interaction is key in processes like opsonization, where antibodies 'tag' pathogens for destruction by these cells. Moreover, the Fc region is involved in activating the complement system, a part of the immune response that helps to clear pathogens.

The structure of an antibody significantly contributes to its function. The Y-shaped molecule consists of two heavy chains and two light chains, connected by disulfide bonds. The arms of the Y (the variable regions) are where antigen binding occurs; these regions are highly variable, allowing antibodies to bind to a vast array of antigens. The stem of the Y (the constant region) determines the class of the antibody and interacts with other parts of the immune system. For example, it can bind to receptors on immune cells (like phagocytes) or activate the complement system. This structure allows antibodies to perform various roles, including neutralization of pathogens, opsonization, and initiation of the complement cascade.

Antibodies contribute to the development of targeted therapies in several ways. Monoclonal antibodies, which are antibodies produced by identical immune cells cloned from a unique parent cell, can be designed to bind specifically to certain proteins or cells. This specificity allows for targeted action against diseases. For example, in cancer therapy, monoclonal antibodies can be engineered to bind to specific cancer cell markers, thereby targeting and destroying these cells. Furthermore, antibodies can be conjugated with drugs, toxins, or radioactive substances to deliver these agents directly to the target cells, increasing the efficacy of the treatment and reducing side effects. Such targeted therapies are being increasingly used in the treatment of various conditions, including autoimmune diseases, cancers, and infectious diseases.

The diversity of antibodies produced in the human body is influenced by several mechanisms. Firstly, during B cell development, the random recombination of gene segments (V, D, and J segments) encoding for the variable regions of antibodies generates a vast array of different antigen-binding sites. This process is known as V(D)J recombination. Additionally, the introduction of random mutations in the variable regions during a process called somatic hypermutation further diversifies the antibody repertoire. Lastly, class switching, where a B cell changes the class of antibody it produces without altering the antigen specificity, adds to the diversity by producing different classes of antibodies (like IgG, IgM, IgA, IgE, and IgD) that can respond to the same antigen in various ways.

Antibodies are able to differentiate between self and non-self antigens through a process called clonal selection. During the development of B cells (which produce antibodies) in the bone marrow, B cells that react strongly to self-antigens are typically eliminated or undergo a process called receptor editing to change their specificity. This process, known as central tolerance, ensures that the surviving B cells and their antibodies are mostly reactive to non-self antigens. Peripheral tolerance mechanisms also exist in the body to inactivate or kill any B cells that may react to self-antigens. Therefore, the immune system is fine-tuned to respond vigorously to foreign antigens while remaining unresponsive to the body's own tissues.